Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type i interferon and autoantibody-secreting cells

Arthritis and Rheumatism

Volumn 64, Issue 2, 2012, Pages 493-503

  Ichikawa, H Travis ^a   Conley, Thomas ^a   Muchamuel, Tony ^b   Jiang, Jing ^b   Lee, Susan ^b   Owen, Teresa ^a   Barnard, Jennifer ^a   Nevarez, Sarah ^a   Goldman, Bruce I ^a   Kirk, Christopher J ^b   Looney, R John ^a   Anolik, Jennifer H ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b ONYX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BORTEZOMIB; CARFILZOMIB; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN G; ONX 0914; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODY-PRODUCING CELLS; AUTOANTIBODIES; BORONIC ACIDS; DISEASE PROGRESSION; HUMANS; INTERFERON TYPE I; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MICE; OLIGOPEPTIDES; PROTEASE INHIBITORS; PYRAZINES;

EID: 84863012127     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.33333     Document Type: Article

References (45)

1. Bongu A, Chang E, Ramsey-Goldman R,. Can morbidity and mortality of SLE be improved? Best Pract Res Clin Rheumatol 2002; 16: 313-32.
2. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580-9. (Pubitemid 39062719)
3. Anolik JH, Barnard J, Owen T, Zheng B, Kemshetti S, Looney RJ, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007; 56: 3044-56. (Pubitemid 47502752)
4. Sabahi R, Anolik JH,. B-cell-targeted therapy for systemic lupus erythematosus. Drugs 2006; 66: 1933-48. (Pubitemid 44771932)
5. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab trial. Arthritis Rheum 2010; 62: 222-33.
6. Kastritis E, Mitsiades CS, Dimopoulos MA, Richardson PG,. Management of relapsed and relapsed refractory myeloma. Hematol Oncol Clin North Am 2007; 21: 1175-215. (Pubitemid 350051353)
7. Li ZW, Chen H, Campbell RA, Bonavida B, Berenson JR,. NF-ÎB in the pathogenesis and treatment of multiple myeloma. Curr Opin Hematol 2008; 15: 391-9.
8. Orlowski RZ, Kuhn DJ,. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008; 14: 1649-57. (Pubitemid 351469448)
9. Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14: 748-55. (Pubitemid 351951516)
10. Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007; 110: 1042-9. (Pubitemid 47312870)
11. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007; 67: 6383-91. (Pubitemid 47037522)
12. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007; 110: 3281-90. (Pubitemid 350106321)
13. O'Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF, et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 2009; 15: 7085-91.
14. Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 2009; 15: 781-7.
15. Nencioni A, Schwarzenberg K, Brauer KM, Schmidt SM, Ballestrero A, Grunebach F, et al. Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood 2006; 108: 551-8. (Pubitemid 44061355)
16. Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000; 9: 664-71. (Pubitemid 32011791)
17. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711-23. (Pubitemid 36350866)
18. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003; 100: 2610-5. (Pubitemid 36297546)
19. Mathian A, Weinberg A, Gallegos M, Banchereau J, Koutouzov S,. IFN-α induces early lethal lupus in preautoimmune (New Zealand Black à- New Zealand White) F1 but not in BALB/c mice. J Immunol 2005; 174: 2499-506. (Pubitemid 40279662)
20. Bekar KW, Owen T, Dunn R, Ichikawa T, Wang W, Wang R, et al. Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum 2010; 62: 2443-57.
21. Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 2009; 15: 781-7.
22. Mensah KA, Mathian A, Ma L, Xing L, Ritchlin CT, Schwarz EM,. Mediation of nonerosive arthritis in a mouse model of lupus by interferon-α- stimulated monocyte differentiation that is nonpermissive of osteoclastogenesis. Arthritis Rheum 2010; 62: 1127-37.
23. Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007; 67: 1783-92. (Pubitemid 46383406)
24. Kozutsumi Y, Segal M, Normington K, Gething MJ, Sambrook J,. The presence of malfolded proteins in the endoplasmic reticulum signals the induction of glucose-regulated proteins. Nature 1988; 332: 462-4. (Pubitemid 18090252)
25. Cascio P, Oliva L, Cerruti F, Mariani E, Pasqualetto E, Cenci S, et al. Dampening Ab responses using proteasome inhibitors following in vivo B cell activation. Eur J Immunol 2008; 38: 658-67.
26. Reimold AM, Iwakoshi NN, Manis J, Vallabhajosyula P, Szomolanyi-Tsuda E, Gravallese EM, et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature 2001; 412: 300-7. (Pubitemid 32691837)
27. Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH,. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A 2003; 100: 9946-51. (Pubitemid 37087048)
28. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dorner T, et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 2006; 6: 741-50. (Pubitemid 44453460)
29. Hoyer BF, Moser K, Hauser AE, Peddinghaus A, Voigt C, Eilat D, et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 2004; 199: 1577-84. (Pubitemid 38780412)
30. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL,. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979; 301: 5-8. (Pubitemid 9226519)
31. Kariuki SN, Franek BS, Kumar AA, Arrington J, Mikolaitis RA, Utset TO, et al. Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus. Arthritis Res Ther 2010; 12: R151.
32. Ehrenstein MR, McSweeney E, Swane M, Worman CP, Goldstone AH, Isenberg DA,. Appearance of anti-DNA antibodies in patients treated with interferon-α. Arthritis Rheum 1993; 36: 279-80. (Pubitemid 23059344)
33. Kalkner KM, Ronnblom L, Karlsson Parra A, Bengtsson M, Olsson Y, Oberg K,. Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. QJM 1998; 91: 393-9. (Pubitemid 28286838)
34. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK,. Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005; 52: 1491-503. (Pubitemid 40663941)
35. Hron JD, Peng SL,. Type I IFN protects against murine lupus. J Immunol 2004; 173: 2134-42. (Pubitemid 38971652)
36. Lu Q, Shen N, Li XM, Chen SL,. Genomic view of IFN-α response in pre-autoimmune NZB/W and MRL/lpr mice. Genes Immun 2007; 8: 590-603. (Pubitemid 350011691)
37. Liu J, Karypis G, Hippen KL, Vegoe AL, Ruiz P, Gilkeson GS, et al. Genomic view of systemic autoimmunity in MRLlpr mice. Genes Immun 2006; 7: 156-68. (Pubitemid 43336058)
38. Ronnblom L, Alm GV,. A pivotal role for the natural interferon α-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med 2001; 194: F59-63. (Pubitemid 34028649)
39. Osawa Y, Iho S, Takauji R, Takatsuka H, Yamamoto S, Takahashi T, et al. Collaborative action of NF-ÎB and p38 MAPK is involved in CpG DNA-induced IFN-α and chemokine production in human plasmacytoid dendritic cells. J Immunol 2006; 177: 4841-52. (Pubitemid 44469820)
40. Adams J,. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4: 349-60. (Pubitemid 38579481)
41. Hirai M, Kadowaki N, Kitawaki T, Fujita H, Takaori-Kondo A, Fukui R, et al. Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis. Blood 2011; 117: 500-9.
42. Badr G, Borhis G, Treton D, Richard Y,. IFNα enhances human B-cell chemotaxis by modulating ligand-induced chemokine receptor signaling and internalization. Int Immunol 2005; 17: 459-67. (Pubitemid 40568121)
43. Giordani L, Sanchez M, Libri I, Quaranta MG, Mattioli B, Viora M,. IFN-α amplifies human naive B cell TLR-9-mediated activation and Ig production. J Leukoc Biol 2009; 86: 261-71.
44. Poeck H, Wagner M, Battiany J, Rothenfusser S, Wellisch D, Hornung V, et al. Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. Blood 2004; 103: 3058-64. (Pubitemid 38451681)
45. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J,. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003; 19: 225-34. (Pubitemid 37011337)